Jefferies Maintains a Buy on Haleon plc (HLN)

Core Viewpoint - Haleon plc (NYSE:HLN) is recognized as one of the best young stocks to buy and hold for 20 years, with a maintained Buy rating and a price target of p450.00 by Jefferies analyst David Hayes [1]. Group 1: Stock Performance and Growth - Despite recent setbacks, including weaker cold and flu product sales in fiscal Q4 2025, Haleon has shown strong growth of over 4% across its portfolio [2]. - The company is expected to face another headwind from the cold and flu season in fiscal Q1 2026, yet it is projected to achieve 4% like-for-like growth [4]. - If Haleon can increase its underlying growth to 5% and achieve 9% growth in emerging markets, its valuation will be well supported [4]. Group 2: Company Overview - Haleon, along with its subsidiaries, is involved in the research, development, manufacturing, and sale of various consumer healthcare products across multiple regions, including North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific [5].